21241-42-9

Basic information

• Product Name: 3-[(1-ADAMANTYLCARBONYL)AMINO]PROPANOIC ACID
• Synonyms: b-Alanine,N-(1-adamantylcarbonyl)- (8CI); N-(Adamantane-1-carbonyl)-b-alanine
• CAS NO: 21241-42-9
• Molecular Formula: C14H21NO3
• Molecular Weight: 251.32100
• Mol File: 21241-42-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 490.7oC at 760 mmHg
• Flash Point: 250.6oC
• Appearance: /
• Vapor Pressure: 5.71E-11mmHg at 25°C
• CAS DataBase Reference: 3-[(1-ADAMANTYLCARBONYL)AMINO]PROPANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(1-ADAMANTYLCARBONYL)AMINO]PROPANOIC ACID(21241-42-9)
• EPA Substance Registry System: 3-[(1-ADAMANTYLCARBONYL)AMINO]PROPANOIC ACID(21241-42-9)

Safety Data

• Hazardous Substances Data: 21241-42-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H21NO3/c16-12(17)1-2-15-13(18)14-6-9-3-10(7-14)5-11(4-9)8-14/h9-11H,1-8H2,(H,15,18)(H,16,17)/p-1

Upstream product

• 2094-72-6 1-Adamantanecarbonyl chloride 
• 107-95-9 3-amino propanoic acid 
• 828-51-3 1-Adamantanecarboxylic acid 
• 16690-93-0 sodium β-alaninate 

Relevant articles and documents

Derivatives of ryanodine and dehydroryanodine

Novel O10eq -derivatives of ryanodine and dehydroryanodine characterized as binding strongly to ryanodine receptor, useful in affecting Ca++ efflux in tissue and also in isolating ryanodine receptor from sarcoplasmic reticulum. Also

Adamantane as a brain-directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with the 1-adamantane moiety

Five AZT (azidothymidine) prodrugs conjugated with the 1-adamantane moiety via an ester bond were synthesized to improve the transport of AZT into the central nervous system (CNS). In in vitro degradation studies with rat and human plasma, it was demonstrated that the prodrugs were degradated enzymatically and converted quantitatively to their parent drug, AZT. As assessed by octanol-buffer partitioning, the prodrugs were much more lipophilic than AZT and were expected to penetrate the blood-brain barrier (BBB) readily. In in vivo studies, in which the prodrugs were administered intravenously to rat, the prodrugs in brain tissue were detected at 7-18 times higher concentrations than AZT in spite of the negligible amount of the prodrug in the cerebrospinal fluid. These results indicate that the introduction to AZT of the 1-adamantane moiety results in the enhancement of the BBB penetration. This pharmaceutical approach would be beneficial for the efficient treatment of the CNS infection by human immunodeficiency virus.